Manulife (Manufacturers Life Insurance)
INZY

Manulife (Manufacturers Life Insurance)’s Inozyme Pharma INZY Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,745
Closed -$57.5K – 2946
2024
Q4 		$57.5K Buy
20,745
+45
+0.2% +$171 ﹤0.01% 2922
2024
Q3 		$108K Sell
20,700
-727
-3% -$3.77K ﹤0.01% 2850
2024
Q2 		$95.6K Buy
21,427
+2,690
+14% +$13K ﹤0.01% 2833
2024
Q1 		$144K Sell
18,737
-5,764
-24% -$31.6K ﹤0.01% 2692
2023
Q4 		$104K Buy
24,501
+9,949
+68% +$35.3K ﹤0.01% 2806
2023
Q3 		$61.1K Sell
14,552
-138
-0.9% -$702 ﹤0.01% 2928
2023
Q2 		$81.8K Buy
+14,690
New +$86.8K ﹤0.01% 2910

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s INZY Position: Q1 2025 in Review

Manulife (Manufacturers Life Insurance) sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 20,745 shares — an estimated $57.5K sold.

Manulife (Manufacturers Life Insurance) first reported a position in INZY in Q2 2023 and held it in 7 quarters. The position peaked at $144K in Q1 2024. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Manulife (Manufacturers Life Insurance) reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 20,745 Inozyme Pharma shares in Q1 2025, an estimated $57.5K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Inozyme Pharma in Q2 2023 and held it in 7 quarters.
  • Manulife (Manufacturers Life Insurance)'s Inozyme Pharma position peaked at $144K in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2025, filed 15 May 2025.